Phase 3 Trial Comparing Docetaxel and Prednisone With and Without Bevacizumab (Avastin)
Principal Investigator: John Deeken, Oncology
Disease Stage: Advanced
A randomized double-blind placebo controlled phase 3 trial comparing docetaxel and prednisone with and without bevacizumab (avastin) in men with hormone refractory prostate cancer.
This study is for men with advanced hormone refractory prostate cancer. This means that the cancer is no longer responding to treatment with hormones. The purpose of this study is to compare the effects of the combination of the chemotherapy drug docetaxel and prednisone (steroid) with the combination of docetaxel, prednisone and the experimental drug bevacizumab on prostate cancer to find out which is better. Bevacizumab is an antibody that we think can block the VEGF protein and inhibit the growth of new blood vessels. Bevacizumab has been approved by the FDA for the treatment of colorectal cancer, but for prostate cancer, it is not FDA-approved and should be considered experimental. Docetaxel and prednisone is one commonly used treatment that has been shown to make some patients with prostate cancer live longer. This research is being done to see if adding bevacizumab to the docetaxel and prednisone will delay the growth of the cancer and allow patients to live longer.
Contact the Lombardi CancerLine to learn more. Phone: 202-444-4000 Email: mailto:LombardiCancerLine@gunet.georgetown.edu